Effect of a conjugated linoleic acid and ω-3 fatty acid mixture on body composition and adiponectin

Obesity

Volumn 16, Issue 5, 2008, Pages 1019-1024

  Sneddon, Alan A ^a   Tsofliou, Fotini ^a   Fyfe, Claire L ^a   Matheson, Ian ^a   Jackson, Diane M ^a   Horgan, Graham ^a   Winzell, Maria S ^b   Wahle, Klaus W J ^c   Ahren, Bo ^b   Williams, Lynda M ^a  

^a ROWETT RESEARCH INSTITUTE   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CONJUGATED LINOLEIC ACID; INSULIN; LEPTIN; OMEGA 3 FATTY ACID;

ADULT; ARTICLE; BLOOD; BODY COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; LINOLEIC ACIDS, CONJUGATED; MALE; MIDDLE AGED; OBESITY;

EID: 42949148605     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.41     Document Type: Article

References (44)

1. Bhattacharya A, Banu J, Rahman M, Causey J, Fernandes G. Biological effects of conjugated linoleic acids in health and disease. J Nutr Biochem 2006;17:789-810.
2. DeLany JP, Blohm F, Truett AA, Scimeca JA, West DB. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999;276:R1172- R1179.
3. Ikemoto S, Takahashi M, Tsunoda N et al. High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils. Metabolism 1996;45:1539-1546.
4. Ruxton C. Health benefits of omega-3 fatty acids. Nurs Stand 2004;18:38-42.
5. West DB, DeLany JP, Camet PM et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998;275:R667-R672.
6. Ryder JW, Portocarrero CP, Song XM et al. Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 2001;50:1149-1157.
7. Blankson H, Stakkestad JA, Fagertun H et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000;130:2943-2948.
8. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr 2004;80:887-895.
9. Risérus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care 2002;25:1516-1521.
10. Risérus U, Vessby B, Arner P, Zethelius B. Supplementation with trans10cis12-conjugated linoleic acid induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. Diabetologia 2004;47:1016-1019.
11. Poirier H, Niot I, Clément L, Guerro-Millo M, Besnard P. Development of conjugated linoleic acid (CLA)-mediated lipoatrophic syndrome in the mouse. Biochimie 2005;87:73-79.
12. Delarue J, Li CH, Cohen R, Corporeau C, Simon B. Interaction of fish oil and a glucocorticoid on metabolic responses to an oral glucose load in healthy human subjects. Br J Nutr 2006;95:267-272.
13. Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. J Nutr Biochem 2006;17:1-13.
14. Glauber H, Wallace P, Griver K, Brechtel, G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988;108:663-668.
15. Ide T. Interaction of fish oil and conjugated linoleic acid in affecting hepatic activity of lipogenic enzymes and gene expression in liver and adipose tissue. Diabetes 2005;54:412-423.
16. Risérus U. Trans fatty acids and insulin resistance. Atheroscler Suppl 2006;7:37-39.
17. Henderson L, Gregory J, Irving K et al. The National Diet and Nutrition Survey: Adults Aged 19-64 years, Volume 2: Energy, Protein, Carbohydrate, Fat and Alcohol Intake. HMSO: London.
18. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1995;854:1-452.
19. Park YW, Heymsfield SB, Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord 2002;26:978-983.
20. Stewart KJ, DeRegis JR, Turner KL et al. Usefulness of anthropometrics and dual-energy x-ray absorptiometry for estimating abdominal obesity measured by magnetic resonance imaging in older men and women. J Cardiopulm Rehabil 2003;23:109-114.
21. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
22. Risérus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. Int J Obes Relat Metab Disord 2001;25:1129-1135.
23. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat in healthy exercising humans. J Int Med Res 2001;29:392-396.
24. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans - metabolic effects. Lipids 2001;36:773-781.
25. Couet C, Delarue J, Ritz P, Antoine JM, Lamisse F. Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes Relat Metab Disord 1997;21:637-643.
26. Gaullier JM, Halse J, Hoivik HO et al. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. Br J Nutr 2007;97:550-560.
27. Fontani G, Corradeschi F, Felici A et al. Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with omega-3 polyunsaturated fatty acids. Eur J Clin Invest 2005;35:499-507.
28. Hill AM, Buckley JD, Murphy KJ, Howe PR. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr 2007;85:1267-1274.
29. Zambell KL, Keim NL, Van Loan MD et al. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. Lipids 2000;35:777-782.
30. Belury MA, Mahon A, Banni S. The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. J Nutr 2003;133:257S-260S.
31. Warner JG Jr, Ullrich IH, Albrink MJ, Yeater RA. Combined effects of aerobic exercise and omega-3 fatty acids in hyperlipidemic persons. Med Sci Sports Exerc 1989;21:498-505.
32. Brilla LR, Landerholm TE. Effect of fish oil supplementation and exercise on serum lipids and aerobic fitness. J Sports Med Phys Fitness 1990;30:173-180.
33. Després JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993;9:452-459.
34. Bjorntorp P. Visceral obesity: a "civilization syndrome". Obes Res 1993;1:206-222.
35. Winzell MS, Pacini G, Ahrén B. Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice. Am J Physiol Endocrinol Metab 2006;290:E347-E354.
36. Cote M, Mauriege P, Bergeron J et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005;90:1434-1439.
37. Yamamoto Y, Hirose H, Saito I et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002;103:137-142.
38. Schaffler A, Herfarth H, Paul G et al. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes 2004;112:383-389.
39. Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf) 2005;62:114-118.
40. Isobe T, Saitoh S, Takagi S et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005;153:91-98.
41. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
42. Abbasi F, Chu JW, Lamendola C et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004;53:585-590.
43. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1996;257:79-83.
44. Itoh M, Suganami T, Satoh N et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007;27:1918-1925.